Vienna Hypothermic Oxygenated Machine Perfusion Study (VIHOMPS)
Vienna Hypothermic Oxygenated Machine Perfusion for Liver Transplantation Study
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: David Pereyra, MD, PhD
- Phone Number: +4314040056210
- Email: david.pereyra@muv.ac.at
Study Contact Backup
- Name: Jule Dingfelder, MD
- Phone Number: +4314040056210
- Email: jule.dingfelder@muv.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Medical University of Vienna
-
Contact:
- David Pereyra, MD, PhD
- Phone Number: +4314040056210
- Email: david.pereyra@muv.ac.at
-
Contact:
- Jule Dingfelder, MD
- Phone Number: +4314040056210
- Email: jule.dingfelder@muv.ac.at
-
Sub-Investigator:
- Gabriela A Berlakovich, Prof, MD
-
Sub-Investigator:
- Georg Györi, MD
-
Sub-Investigator:
- Thomas Soliman, Prof, MD
-
Sub-Investigator:
- Andreas Salat, Prof, MD
-
Sub-Investigator:
- Gerd Silberhumer, Prof, MD
-
Sub-Investigator:
- Julia Jedamzik, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients undergoing liver transplantation with the use of hypothermic oxygenated machine perfusion
- age ≥ 18 years
Exclusion Criteria:
- pregnancy
- partial grafts
- the anatomical integrity of the liver is not preserved in a way that makes the perfusion of the liver possible
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of ischemic-type biliary lesions
Time Frame: Within one year after liver transplantation
|
Non-anastomotic stenosis, post-transplant cholangiopathy
|
Within one year after liver transplantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of early allograft dysfunction
Time Frame: Evaluated within the first 7 postoperative days
|
Deviation of bilirubin, transaminases or international normalised ratio
|
Evaluated within the first 7 postoperative days
|
|
Rate of primary non-function
Time Frame: Evaluated in the immediate postoperative period, specifically within the first postoperative week
|
Evaluated in the immediate postoperative period, specifically within the first postoperative week
|
|
|
Incidence of re-transplantation
Time Frame: Evaluated in the immediate postoperative period, specifically within the first postoperative week
|
Evaluated in the immediate postoperative period, specifically within the first postoperative week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Gabriela A Berlakovich, Prof, MD, Medical University of Vienna, Division of Transplantation
- Study Director: Georg Györi, MD, Medical University of Vienna, Division of Transplantation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1610/2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.